S. 272: Protect Infant Formula from Contamination Act

The Protect Infant Formula from Contamination Act aims to enhance the safety and oversight of infant formula production and distribution. Here is a summary of the key provisions of the bill:

Notification Requirements for Testing

The bill amends existing laws regarding the testing of infant formula for harmful microorganisms and toxic elements. Key changes include:

• If a manufacturer discovers positive test results for harmful microorganisms in their infant formula, they must notify the Secretary of Health and Human Services within one business day.
• Manufacturers are required to consult with the Secretary on how to properly isolate affected products and may need to cease distribution and dispose of those products.
• Manufacturers must promptly provide results from positive samples to the Secretary.
• The Secretary will respond to manufacturers within one business day to begin discussions on further investigation and necessary corrective actions.
• Within 90 days of receiving a notification, the Secretary must confirm whether the manufacturer has conducted an appropriate investigation into the contamination and report on findings.

Improving Reporting for Safety and Supply

The act outlines new reporting requirements intended to improve safety and supply chain transparency for infant formula:

• A progress report must be issued by the Secretary within 180 days of the bill's enactment, detailing implementation of recommendations from a prior FDA report on enhancing the infant formula market.
• Subsequent quarterly reports on supply chain data will be submitted for five years to various congressional committees, focusing on in-stock rates and other critical supply chain metrics.
• The Secretary is directed to engage with the Department of Agriculture and other agencies to address both immediate needs and long-term resilience in the infant formula market.
• Reports on the adequacy of infant formula supply will be submitted at the one-year, three-year, and five-year marks post-enactment, including stakeholder engagement to identify best practices for maximizing supply and safety.

Consultation with Stakeholders

The Secretary is tasked with collaborating with stakeholders in the infant formula industry to gather evidence-based practices that can be used to enhance both safety and availability of infant formula. This includes reviewing testing practices and manufacturers' actions regarding contamination events.

Relevant Companies

• KO (The Coca-Cola Company) - As a food and beverage company, they may have an interest in infant formula products and could be affected by compliance with the new testing and notification requirements.
• MDLZ (Mondelez International, Inc.) - As a manufacturer of a wide range of food products, including those for infants, Mondelez may need to adapt its safety and testing protocols to meet the new regulations.
• NVS (Novartis AG) - As a healthcare company with a portfolio that may include nutritional products, Novartis would be subject to any new safety regulations outlined in the bill.